Leaderboards/Prostate Cancer Treatment and Research

Prostate Cancer Treatment and Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Tyler B. Kratzer
American Cancer Society
2
James P Buteau
Peter MacCallum Cancer Centre
3
Jaleh Fallah
United States Food and Drug Administration
4
Haitham Elmarakeby
Broad Institute
5
Fanying Tang
AbbVie (United States)
6
Jonathan Welti
Institute of Cancer Research
7
Cameron Herberts
Natera (United States)
8
Emily Grist
The University of Adelaide
9
Louise Kostos
Peter MacCallum Cancer Centre
10
Madeleine J. Karpinski
Deutsches Konsortium für Translationale Krebsforschung

Papers

1
Publication in The Lancet Oncology (2024) [79 citations, W4401067277]
The Lancet Oncology|2024
79 cit.
2
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Journal of Clinical Oncology|2024
74 cit.
3
Prostate cancer statistics, 2025
CA A Cancer Journal for Clinicians|2025
55 cit.
4
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
The Lancet Oncology|2025
34 cit.
5
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
Clinical Cancer Research|2024
27 cit.
6
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&amp;T
Journal of Nuclear Medicine|2024
26 cit.
7
Publication in European Urology (2025) [23 citations, W4410025420]
European Urology|2025
23 cit.
8
Publication in Cell (2025) [21 citations, W4413680397]
Cell|2025
21 cit.
9
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis
JNCI Journal of the National Cancer Institute|2024
12 cit.
10
Publication in Journal of Nuclear Medicine (2025) [11 citations, W4407765566]
Journal of Nuclear Medicine|2025
11 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Alison Y. Zhang
The University of Sydney
2
Spencer R. Rosario
Roswell Park Comprehensive Cancer Center
3
Charlotte F. Kweldam
Maasstad Ziekenhuis
4
Jean‐Philippe Theurillat
Institute of Oncology Research
5
Wassim Abida
Memorial Sloan Kettering Cancer Center
6
Martin Bögemann
University Hospital Münster
7
Ping Mu
Yale Cancer Center
8
Wouter R. Karthaus
École Polytechnique Fédérale de Lausanne
9
Jillian R Love
Memorial Sloan Kettering Cancer Center
10
Jiantong Cai
Washington University in St. Louis

Papers

1
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
The Lancet Oncology|2022
266 cit.
2
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Nature Cancer|2022
149 cit.
3
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
European Urology|2023
97 cit.
4
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
European Urology|2022
60 cit.
5
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Cancer Cell|2023
51 cit.
6
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Clinical Cancer Research|2024
50 cit.
7
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Cancer Discovery|2024
44 cit.
8
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Nature Medicine|2025
32 cit.
9
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer
Nature Communications|2024
30 cit.
10
The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer
Cancer Research|2023
22 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Charles L. Sawyers
Memorial Sloan Kettering Cancer Center
2
Johann S. de Bono
Royal Marsden NHS Foundation Trust
3
Arul M. Chinnaiyan
Howard Hughes Medical Institute
4
Howard I. Scher
Memorial Sloan Kettering Cancer Center
5
Chawnshang Chang
China Medical University
6
Mark A. Rubin
University of Bern
7
Arul M. Chinnaiyan
University of Michigan
8
Peter S. Nelson
Fred Hutch Cancer Center
9
Jonathan I. Epstein
Johns Hopkins University
10
Eric J. Small
CancerCare Manitoba

Papers

1
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
New England Journal of Medicine|2001
5.2k cit.
2
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
New England Journal of Medicine|2012
4.6k cit.
3
Abiraterone and Increased Survival in Metastatic Prostate Cancer
New England Journal of Medicine|2011
4.4k cit.
4
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Science|2005
3.9k cit.
5
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Neoplasia|2004
3.7k cit.
6
Integrative Clinical Genomics of Advanced Prostate Cancer
Cell|2015
3.6k cit.
7
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
New England Journal of Medicine|2009
3.6k cit.
8
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
The Lancet|2010
3.3k cit.
9
The polycomb group protein EZH2 is involved in progression of prostate cancer
Nature|2002
2.7k cit.
10
FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis
Cell|1995
2.4k cit.

Reagents for Prostate Cancer Treatment and Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cytek Biosciences

PE Anti-Mouse CD274 (PD-L1, B7-H1) (10F.9G2)

Cited in 21 papers
#50-1243
View Evidence →
Cell Signaling TechnologyEvidence 65

Synaptophysin (7H12) Mouse Monoclonal Antibody (BSA and Azide Free)

Cited in 16 papers
#36451$865
View Evidence →
Cell Signaling TechnologyEvidence 66

Tyrosine Hydroxylase (E2L6M) Feline Chimeric Monoclonal Antibody

Cited in 14 papers
#69079$166,369
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Prostate Specific Antigen Membrane Antigen

Cited in 32 papers
#M3620
View Evidence →
Millipore

Anti-Androgen Receptor, PG-21

Cited in 25 papers
#06-680
View Evidence →
Cell Signaling Technology

PINCH (5G7) Mouse Monoclonal Antibody

Cited in 24 papers
#11890$158,348
View Evidence →